Understand what CA-125 measures, why levels rise, how the result is interpreted and why this tumour marker cannot diagnose or exclude ovarian cancer on its own.
CA-125 (Cancer Antigen 125) is a blood-based tumour marker frequently used in the assessment and monitoring of epithelial ovarian cancer. It can also increase in several benign gynaecological conditions and other diseases. Therefore, an elevated result does not automatically mean cancer, and a normal result does not completely exclude it.
The cutoff of 35 U/mL is commonly used, but the laboratory's validated reference interval and the clinical context take precedence.
1. What Is the CA-125 Blood Test?
CA-125 is an antigen associated with MUC16, a large cell-surface glycoprotein. It can be released into the circulation by certain normal tissues and by some malignant cells.
In clinical practice, the test is most closely associated with epithelial ovarian cancer, including cancers arising in the fallopian tubes and primary peritoneum. However, CA-125 is not specific to one organ or one disease.
Why is CA-125 requested?
- To monitor treatment response in selected patients with ovarian cancer.
- To help assess a suspicious adnexal or pelvic mass alongside clinical findings and imaging.
- To monitor selected patients after treatment for possible recurrence, when appropriate.
- As part of an individualised assessment in certain patients with a strong inherited or familial risk, under specialist guidance.
2. CA-125 Normal Range and Interpretation
Many laboratories use a reference limit of less than or equal to 35 U/mL, although the exact reporting convention and reference interval may differ by assay.
| CA-125 result | General interpretation | Important consideration |
|---|---|---|
| Within the laboratory reference interval | Not elevated by that laboratory's criteria | Does not exclude early ovarian cancer or every ovarian cancer subtype. |
| Above the reference limit | Elevated tumour marker | May occur in benign disease, physiological conditions or malignancy. |
| Markedly elevated | Requires clinical assessment | Raises concern in the appropriate context but is not independently diagnostic of cancer. |
| Increasing on serial testing | Potentially significant trend | Interpret with symptoms, treatment history, examination and imaging. |
| Decreasing during treatment | May indicate a biochemical response | Must be correlated with clinical and radiological response. |
3. What Causes High CA-125 Levels?
Elevated CA-125 may occur in both malignant and non-malignant conditions.
Benign and physiological causes
- Menstruation: levels may rise during the menstrual cycle.
- Pregnancy: elevations can occur, particularly in certain stages or circumstances.
- Endometriosis: a recognised cause of increased CA-125.
- Uterine fibroids: may be associated with elevated levels.
- Pelvic inflammatory disease: inflammation can increase the marker.
- Liver disease: particularly when associated with ascites.
- Peritoneal inflammation or fluid accumulation: can contribute to elevations.
Malignant causes
- Epithelial ovarian cancer.
- Fallopian tube cancer.
- Primary peritoneal cancer.
- Some endometrial cancers and other malignancies, depending on the clinical setting.
Practical example: A premenopausal woman with endometriosis and CA-125 of 80 U/mL cannot be assumed to have ovarian cancer. Conversely, a postmenopausal woman with a complex adnexal mass and an elevated CA-125 warrants careful assessment even if she has few symptoms.
4. CA-125 and Ovarian Cancer: What Does the Result Tell Us?
CA-125 is most useful when interpreted as one component of a broader clinical assessment.
Early-stage ovarian cancer
CA-125 may remain within the reference interval in early-stage disease. Some ovarian cancers do not produce substantial elevations, so a normal result cannot be used to rule out malignancy.
Advanced ovarian cancer
CA-125 is frequently elevated in advanced epithelial ovarian cancer, especially when there is substantial peritoneal involvement. However, the degree of elevation varies between patients and tumour types.
Pelvic mass evaluation
When ultrasound identifies an ovarian or adnexal mass, the clinician may consider CA-125 alongside:
- Transvaginal or pelvic ultrasound morphology.
- Age and menopausal status.
- Symptoms and physical examination.
- Family history and inherited cancer risk.
- Additional imaging or specialist assessment when indicated.
In selected cases, clinicians may use validated risk assessment approaches. CA-125 alone is not sufficient to establish the diagnosis. Definitive diagnosis generally requires histopathological evaluation of tissue.
5. Can CA-125 Be Used for Routine Ovarian Cancer Screening?
The reasons include:
- False positives: benign conditions can elevate CA-125, leading to unnecessary investigations and potentially harmful procedures.
- False negatives: some ovarian cancers, particularly early-stage disease, may not produce elevated CA-125.
- Limited screening benefit: routine testing has not demonstrated a clear reduction in ovarian cancer mortality in average-risk populations.
People with a strong family history of ovarian or related cancers, or known inherited variants such as BRCA1/BRCA2, should discuss personalised risk assessment with a qualified clinician or genetic counselling service. CA-125 should not be treated as a stand-alone reassurance or screening strategy.
6. CA-125 Trends During Cancer Treatment
In patients whose ovarian cancer produces elevated CA-125 at baseline, serial measurements may help clinicians assess biochemical trends during and after treatment.
| Trend | Possible meaning | What to consider |
|---|---|---|
| Consistent decline | May support a response to treatment | Correlate with symptoms, examination and imaging. |
| Stable level | May indicate stable marker production | Interpret according to the treatment phase and clinical findings. |
| Confirmed rise over time | May indicate progression or recurrence | Assess the full clinical picture before making treatment decisions. |
| Small isolated fluctuation | May reflect biological or analytical variation | Avoid overinterpreting a single result. |
A rising CA-125 does not automatically mean that treatment should change. Likewise, a falling value alone does not prove that all cancer has disappeared. Decisions should be made by the treating oncology team using the overall clinical evidence.
7. Laboratory Considerations: What Every Lab Professional Should Know
Specimen and preparation
- Specimen: serum is commonly used; follow the specific assay manufacturer's instructions.
- Fasting: usually not required.
- Method: commonly an automated immunoassay, with the platform depending on the laboratory.
- Units: usually U/mL or kU/L, depending on the reporting system.
Analytical interpretation
- Use the reference interval and decision limits validated for the assay in use.
- When monitoring serial results, use the same laboratory and assay platform whenever practical.
- Consider analytical interference if the result is inconsistent with the clinical picture; consult the manufacturer and laboratory procedures.
- Check specimen integrity, instrument flags and quality-control status before releasing an unexpected result.
- Do not directly compare numerical values across different assay platforms without considering method-related differences.
8. When Should an Elevated CA-125 Result Be Evaluated?
Medical assessment is particularly important when an elevated result occurs with persistent or progressive symptoms such as:
- Persistent abdominal bloating or increasing abdominal size.
- Pelvic or abdominal pain or pressure.
- Feeling full quickly or difficulty eating usual portions.
- New urinary urgency or frequency.
- An abnormal pelvic ultrasound or a palpable mass.
These symptoms are common and often have non-cancerous causes. However, persistent symptoms, especially when new or worsening, should not be dismissed because CA-125 is normal. Seek urgent medical care for severe or sudden abdominal pain, fainting or other acute symptoms.
9. Frequently Asked Questions (FAQs)
1. What is the normal CA-125 level?
A commonly used upper reference limit is 35 U/mL. The range printed on the individual laboratory report should be used for interpretation.
2. Does CA-125 above 35 mean cancer?
No. Menstruation, endometriosis, fibroids, pelvic inflammation, pregnancy and liver disease can also increase CA-125. Clinical assessment is needed to determine the likely cause.
3. Can ovarian cancer occur with normal CA-125?
Yes. CA-125 may be normal in early-stage ovarian cancer and in some tumour types. A normal result should not override suspicious symptoms or imaging.
4. Can CA-125 rise during periods?
Yes. Menstruation can cause a temporary increase. The significance of an elevated result depends on the timing, symptoms and clinical context.
5. Is CA-125 a test for fertility or infertility?
CA-125 is not a routine fertility test. It may be elevated in conditions such as endometriosis, but it cannot independently diagnose endometriosis or establish fertility status.
6. Is CA-125 useful after ovarian cancer treatment?
It can be useful for selected patients, particularly when the marker was elevated initially. The value of monitoring and any action taken should be individualised by the oncology team.
7. Does a very high CA-125 confirm ovarian cancer?
No. A markedly elevated result can increase concern, especially when supported by suspicious imaging, but it is not a stand-alone cancer diagnosis.
8. Is fasting required for CA-125?
Usually not. Follow any specific instructions provided by the testing laboratory.
10. Conclusion
CA-125 is an important tumour marker in the evaluation and monitoring of selected patients with ovarian cancer. Its major limitation is lack of specificity: benign gynaecological conditions, menstruation and other diseases can also increase its concentration.
The correct approach is to interpret CA-125 alongside clinical history, menopausal status, imaging and, when indicated, histopathology. Neither an elevated result nor a normal result should be used in isolation to diagnose or exclude ovarian cancer.
References and Further Reading
- MedlinePlus — CA-125 Blood Test (Ovarian Cancer)
- American College of Obstetricians and Gynecologists — Can I get a CA-125 test to make sure I don't have ovarian cancer?
- American Cancer Society — Can Ovarian Cancer Be Found Early?
Medical disclaimer: This article is intended for educational purposes and does not replace medical advice, diagnosis or treatment. Test results should be interpreted by a qualified healthcare professional in the context of the individual patient.
LabDecoded | Laboratory Medicine Explained
0 Comments